<DOC DOCNO="nw/wsj/03/wsj_0318@0318@wsj@nw@en@on">
<ENAMEX TYPE="ORG">Lyphomed Inc.</ENAMEX> , <ENAMEX TYPE="GPE">Rosemont</ENAMEX> , <ENAMEX TYPE="GPE">Ill.</ENAMEX> , and <ENAMEX TYPE="ORG">Medco Research Inc.</ENAMEX> , <ENAMEX TYPE="GPE">Los Angeles</ENAMEX> , said <ENAMEX TYPE="ORG">the Food and Drug Administration</ENAMEX> granted full marketing approval for a new drug for the treatment of a condition in which the heart beats <ENAMEX TYPE="CARDINAL">between 150 and 200</ENAMEX> beats a minute .
The condition , known as paroxysmal supraventricular tachycardia , leads to dizziness and fainting .
The typical healthy heart beats <ENAMEX TYPE="CARDINAL">70</ENAMEX> times a minute .
The drug , called adenocard , returns the heart to a normal rhythm within <ENAMEX TYPE="TIME">seconds</ENAMEX> , according to <ENAMEX TYPE="ORG">Lyphomed</ENAMEX> .
<ENAMEX TYPE="ORG">Medco Research</ENAMEX> developed the drug and licensed it to <ENAMEX TYPE="ORG">Lyphomed</ENAMEX> for sale in the <ENAMEX TYPE="GPE">U.S.</ENAMEX> and <ENAMEX TYPE="GPE">Canada</ENAMEX> .
</DOC>
